Veiledende retningslinjer for diagnostisering og ... - Helse Stavanger

Behandling
1. Black JD, Dolly JO. Interaction of 125i-labelled
botulinum neurotoxin with nerveterminals. J
Cell Biol 1986; 103: 521-34.
2. De PaivaA, Meunier FA, Molgo J, Aoki KR, Dolly
JO. Functional repair of nmotor endplates
after botulinum neurotoxin type A poisoning:
biphasic switch of synaptic activity between
nerve sprouts and their parent terminals. Proc.
Natl. Acad.Sci.USA 1999; 96:3200-5.
3. Scott AB. Botulinum toxin injection into extraocular
muscles as an alternative to strabismus
surgery. J Pediatr Ophtal Strabismus 1980; 171:
21-5.
4. Roggenkamper P, Jost WH, Bihari K, Comes G,
Grafe S. Efficacy and safety of a new botulinum
toxin type. A free of complexing proteins in the
treatment of blepharospasm. J Neural Transm
2006; 113: 303-12.
5. Benecke R, Jost WH, Konovsky P et al. A new
botulinum toxin type. A free of complexing
proteins for treatment of cervical dystonia.
Neurology 2005; 64: 1949-51.
6. Sampaio C, Ferreira JJ, Simoes F et al.
DYSBOT: a single -blind randomised parallel
study to determine whether any differences
can be detected in the efficacy and tolerability
of two formulations of botulinum toxin type A
-Dysport and Botox- assuming a ratio of 4:1 .
Mov Disord 1997; 12: 1013-18.
7. Lew MF, Adornato BT, Duane DD, et al.
Botulinum toxin type B: a double-blind,
placebo controlled, safety and efficacy study in
cervical dystonia. Neurology 1997; 49: 701-7.
8. Brashear A, Lew MF, Dykstra DD et al. Safety
and efficacy of NeuroBloc (botulinum toxin
type B) in type A responsive cervical dystonia.
Neurology 1999; 53: 1439-1446.
9. Brin MF, Lew MF, Adler CH et al. Safety and
efficacy of NeuroBloc (botulinum toxin type) in
type A-resistant cervical dystonia. Neurology
1999; 53: 1431-1438.
10. Brin M, Comella CL, Jankovic J, et al. Long-
Term Treatment with Botulinum Toxin Type A
in Cervical Dystonia Has Low Immunogenicity
by Mouse Protection Assay. Mov Disord 2008;
23(10): 1353-60.
11. Jankovic J, Hunter C, Dolimbek BZ et al.
Clinicoimmunologic aspects of botulinum
toxin type B treatment of cervical dystonia.
Neurology 2006; 67:2333-5.
60
Oral medikasjon
1. Jankovic J. Treatment of hyperkinetic
movement disorders. Lancet Neurol 2009; 8:
844-56.
2. Burke RE, Fahn S, Marsden CD. Torsion
dystonia: A double-blind, prospective trial of
high-dosage trihexyphenidyl. Neurology 1986;
36: 160-4.
Kirurgisk behandling
1. Dietrichs E. Bevegelsesforstyrrelser og
basalganglienes funksjon. Tidsskr Nor
Legeforen. 2008;128:1968-71
2. Benabid AL, Pollak P, Gervason C, et al.
Long-term suppression of tremor by chronic
stimulation of the ventral intermediate
thalamic nucleus. Lancet 1991; 337: 403-6.
3. Schuurman PR, Bosch DA, Bossuyt PM, et al. A
comparison of continuous thalamic stimulation
and thalamotomy for suppression of severe
tremor. N Engl J Med 2000; 342:461-8.
4. Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s
posteroventral pallidotomy in the treatment of
Parkinson’s disease. J Neurosurg 1992; 77(3):
487-8.
5. Coubes P, Echenne B, Cif L, et al. Electrical
stimulation of the internal globus pallidus
in generalized dystonia. Mov Disord 2002 ;
17(Suppl. 5): S 6.
6. Cif L, El Fertit H, Vayssiere N, et al. Treatment
of dystonic syndromes by chronic electrical
stimulation of the internal globus pallidus. J
Neurosurg Sci 2003; 47: 52-5.
7. Vidailhet M, Vercueil L, Houeto JL, et al.
Bilateral Deep-Brain Stimulation of the Globus
Pallidus in Primary Generalized Dystonia. New
Engl J Med 2005; 352: 459-67.
8. Kupsch A, Benecke R, Mueller J, et al, for
the Deep-Brain Stimulation for Dystonia Study
Group. Pallidal Deep-Brain Stimulation in
Primary Generalized or Segmental Dystonia. N
Engl J Med 2006; 355: 1978-90.
9. Mueller J, Skogseid IM, Benecke R, et al, for
the Deep-Brain Stimulation for Dystonia Study
Group. Pallidal deep brain stimulation improves
quality of life in segmental and generalized
dystonia: Results from a prospective,
randomized sham-controlled trial. Mov Disord
2007; Oct.31, E-pub ahead of print.